A detailed history of Commonwealth Equity Services, LLC transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 50,100 shares of PLX stock, worth $52,605. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,100
Previous 50,100 -0.0%
Holding current value
$52,605
Previous $89,000 29.21%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 23, 2023

SELL
$1.49 - $2.02 $149 - $202
-100 Reduced 0.2%
50,100 $83,000
Q2 2023

Aug 10, 2023

BUY
$2.0 - $3.36 $200 - $336
100 Added 0.2%
50,200 $100,000
Q4 2022

Feb 07, 2023

BUY
$1.02 - $1.37 $51,102 - $68,637
50,100 New
50,100 $68,000
Q1 2022

May 04, 2022

SELL
$0.81 - $1.17 $32,634 - $47,139
-40,290 Closed
0 $0
Q4 2021

Jan 31, 2022

BUY
$0.81 - $1.33 $32,634 - $53,585
40,290 New
40,290 $33,000

Others Institutions Holding PLX

About Protalix BioTherapeutics, Inc.


  • Ticker PLX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,753,400
  • Market Cap $52.2M
  • Description
  • Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...
More about PLX
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.